down arrow

VYNE Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92941V3087
USD
0.37
0.02 (4.61%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.370.38

52 Week

0.284.30
Valuation
Technical
Day's Volume

CASH

395.34 k

Shareholding (Mar 2025)

FII

0.41%

Held by 5 FIIs

DII

87.78%

Held by 6 DIIs

Promoter

7.07%

How big is VYNE Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, VYNE Therapeutics, Inc. has a market capitalization of 15.31 million and reported net sales of 0.60 million with a net profit of -42.16 million over the latest four quarters. Shareholder's funds are 52.09 million, and total assets amount to 66.91 million.

As of Jun 18, VYNE Therapeutics, Inc. has a market capitalization of 15.31 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.60 million, while the sum of net profit for the same period is -42.16 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 52.09 million, and total assets amount to 66.91 million.

Read More

What does VYNE Therapeutics, Inc. do?

22-Jun-2025

VYNE Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for pruritus related to dermatologic conditions, with a market cap of $15.31 million and recent net sales of $0 million. The company is currently operating at a loss, with a net profit of -$9 million as of March 2025.

Overview: <BR>VYNE Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for pruritus associated with dermatologic conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 15.31 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.14 <BR>Return on Equity: -95.55% <BR>Price to Book: 0.35<BR><BR>Contact Details: <BR>Address: 520 U.S. Highway 22, Suite 204, BRIDGEWATER NJ: 08807 <BR>Tel: 1 650 4861416 <BR>Fax: 1 302 6555049 <BR>Website: http://www.menlotherapeutics.com/

Read More

Who are in the management team of VYNE Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of VYNE Therapeutics, Inc. includes CEO David Domzalski, Directors Sharon Barbari, Rex Bright, Anthony Bruno, Independent Directors Patrick LePore and Elisabeth Sandoval, who oversee the company's strategic direction and operations.

As of March 2022, the management team of VYNE Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. David Domzalski, Chief Executive Officer and Director<BR>- Ms. Sharon Barbari, Director<BR>- Mr. Rex Bright, Director<BR>- Mr. Anthony Bruno, Director<BR>- Mr. Patrick LePore, Independent Director<BR>- Ms. Elisabeth Sandoval, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is VYNE Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of March 9, 2023, VYNE Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in a price to book value of 0.38, an EV to EBITDA ratio of 0.74, a troubling -95.55% return on equity, and a year-to-date stock performance decline of -72.71%.

As of 9 March 2023, the valuation grade for VYNE Therapeutics, Inc. has moved from risky to does not qualify, indicating significant concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a price to book value of 0.38 and an EV to EBITDA ratio of 0.74. Notably, the return on equity (ROE) stands at a concerning -95.55%, which further supports the notion of overvaluation.<BR><BR>In comparison to its peers, VYNE Therapeutics has a less favorable position, with NanoViricides, Inc. and Mangoceuticals, Inc. also classified as does not qualify, but with EV to EBITDA ratios of -2.0886 and -2.0415, respectively. The company's recent stock performance has been dismal, with a year-to-date return of -72.71%, contrasting sharply with the S&P 500's gain of 2.44%. Overall, these indicators suggest that VYNE Therapeutics is overvalued in the current market environment.

Read More

Is VYNE Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, VYNE Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish MACD, moving averages, and KST, while significantly underperforming the S&P 500 with a year-to-date return of -90.75%.

As of 5 August 2025, the technical trend for VYNE Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST across both weekly and monthly periods. The Bollinger Bands indicate a mildly bearish trend on the weekly and bearish on the monthly. Additionally, the Dow Theory shows a bearish trend on the monthly, while the OBV is mildly bearish on the monthly. <BR><BR>In terms of performance, VYNE has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -90.75% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

-99.07%

stock-summary
Price to Book

0.19

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.86%
0%
17.86%
6 Months
-62.49%
0%
-62.49%
1 Year
-86.78%
0%
-86.78%
2 Years
-89.22%
0%
-89.22%
3 Years
64.56%
0%
64.56%
4 Years
-97.72%
0%
-97.72%
5 Years
-99.69%
0%
-99.69%

VYNE Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is VYNE Therapeutics, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for VYNE Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST across both weekly and monthly periods. The Bollinger Bands indicate a mildly bearish trend on the weekly and bearish on the monthly. Additionally, the Dow Theory shows a bearish trend on the monthly, while the OBV is mildly bearish on the monthly. In terms of performance, VYNE has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -90.75% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-48.65%
EBIT Growth (5y)
9.55%
EBIT to Interest (avg)
-28.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.14
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
71.08%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.38
EV to EBIT
0.74
EV to EBITDA
0.74
EV to Capital Employed
5.52
EV to Sales
-33.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
747.97%
ROE (Latest)
-95.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (4.74%)

Foreign Institutions

Held by 5 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -50.00% vs 100.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 33.72% vs 28.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.50",
          "val2": "-9.20",
          "chgp": "18.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-8.60",
          "chgp": "33.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-109,304.30%",
          "val2": "-45,529.70%",
          "chgp": "-6,377.46%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 25.00% vs -20.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -42.65% vs 17.70% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.40",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-43.60",
          "val2": "-29.30",
          "chgp": "-48.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.80",
          "val2": "-27.90",
          "chgp": "-42.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-87,099.80%",
          "val2": "-69,004.70%",
          "chgp": "-1,809.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.10
0.20
-50.00%
Operating Profit (PBDIT) excl Other Income
-7.50
-9.20
18.48%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.70
-8.60
33.72%
Operating Profit Margin (Excl OI)
-109,304.30%
-45,529.70%
-6,377.46%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -50.00% vs 100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 33.72% vs 28.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.50
0.40
25.00%
Operating Profit (PBDIT) excl Other Income
-43.60
-29.30
-48.81%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-39.80
-27.90
-42.65%
Operating Profit Margin (Excl OI)
-87,099.80%
-69,004.70%
-1,809.51%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 25.00% vs -20.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -42.65% vs 17.70% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About VYNE Therapeutics, Inc. stock-summary
stock-summary
VYNE Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing Technology (MST). The Company has a commercial-stage product, AMZEEQ, and several late-stage product candidates. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as a once-daily oral tablet therapy.
Company Coordinates stock-summary
Company Details
520 U.S. Highway 22, Suite 204 , BRIDGEWATER NJ : 08807
stock-summary
Tel: 1 650 4861416
stock-summary
http://www.menlotherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."